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Microchimerism after liver transplantation is considered to promote graft tolerance or 
tissue repair, but its significance is controversial. By using multiplex polymerase chain 
reaction (PCR) of short tandem repeat (STR) loci after laser capture microdissection of 
hepatocyte nuclei, we compared the proportions of recipient-derived hepatocytes in 
long-term stable liver allografts and late dysfunctional allografts caused by chronic 
rejection or idiopathic post-transplantation hepatitis. Through fluorescence in situ 
hybridization (FISH), we also analyzed the presence of recipient-derived Y-positive 
hepatocytes in the biopsies of livers transplanted from female donors to male recipients. 
The study population comprised 24 pediatric liver transplant recipients who survived 
with the initial graft, whose 10-year protocol biopsy records were available, and who 
had normal liver function (stable graft, SG; n = 13) or a late dysfunctional graft (LDG; n 
= 11) with similar follow-up periods (mean 10.8 years in the SG group and 11.2 years in 
the LDG group). STR analysis revealed that hepatocyte chimerism occurred in 7 of 13 
(54%) SGs and 5 of 11 (45%) LDGs (p = 0.68). The proportion of hepatocyte chimerism 
was low, with a mean of 3% seen in 2 of 3 female-to-male transplanted livers (one each 
of SG and LDG). 
In conclusion, hepatocyte chimerism was a constant event. The extent of engraftment of 
recipient-derived hepatocytes does not seem to correlate with the degree of hepatic 









ALT, alanine aminotransferase; AST, aspartate aminotransferase; CR, chronic rejection; 
FISH, fluorescence in situ hybridization; FFPE, formalin-fixed, paraffin-embedded; 
G-CSF, granulocyte colony-stimulating factor; IPTH, idiopathic post-transplantation 
hepatitis; LDG, late dysfunctional graft; PCR, polymerase chain reaction; SG, stable 





In contrast to other transplanted organs, the liver has been shown to be capable of 
inducing tolerance. The presence of chimerism may be one explanation for how the liver 
induces tolerance [1]. Lagaaij et al. [2] have demonstrated how the replacement of donor 
endothelial cells by those of a recipient is correlated with vascular rejection in renal 
transplantation. In liver transplantation, the progressive engraftment by the recipient’s 
inflammatory cells (i.e., Kupffer cells) soon after transplantation has been well 
described [3-7]. Meanwhile, Pons et al. [8] reported that endothelial cell chimerism does 
not influence allograft tolerance in liver transplant patients, and Tanaka et al. [9] 
observed that endothelial cell chimerism is a time-dependent event after liver 
transplantation independent of graft dysfunction. A few studies have demonstrated 
human intragraft chimerism in hepatocytes [4,7,10-14]. Previous reports have shown 
that hepatocyte chimerism occurs early after transplantation, from 1 week to as late as 
63 months after surgery, and that the proportion of patients in whom this has occurred 
has been low [4,12,14]. The significance of hepatocyte chimerism to transplant outcome 
has not yet been determined. 
 
In cases of sex mismatch between the graft and the recipient, the identification of the Y 
chromosome using in situ hybridization is widely used to study intragraft chimerism 
[3,5-8,10]. However, this approach has limitations because it is only applicable to cases 
of sex-mismatched grafts, and the Y chromosome is not always detectable, even in 
males. The in situ hybridization procedure holds the potential of causing damage to 
antigens, leading to a low sensitivity [6,7,10]. On the other hand, there is a less 
damaging procedure that uses short tandem repeats (STR) consisting of highly 
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polymorphic tetranucleotide repeat sequences that are distributed throughout the 
genome. The use of these markers for the assessment of chimerism has the advantage of 
being independent from sex mismatch, and this technique requires only small samples 
[15]. An approach combining laser capture microdissection of target cells with 
subsequent polymerase chain reaction (PCR) analyzing highly polymorphic STR 
markers to detect hepatocytes of recipient origin enabled us to investigate a great 
number of liver tissue samples without limitations [11]. There have been only two 
reports detecting hepatocyte chimerism in liver allografts using this method [4,11]. The 
technique in one of the studies was to manually microdissect the liver acini so that 
contamination of the hepatocyte samples by blood cells could not be avoided [4]. 
 
The consequences of the phenomenon of microchimerism are still unknown. 
Microchimerism may promote graft tolerance or participate in tissue repair after 
epithelial damage [16]. The chimeric cells are thought to be derived from recipient stem 
cells. The mechanism of microchimerism, whether transdifferentiation [10,17,18] or cell 
fusion [19-21], is unknown. Because of the possibility of hepatocyte chimerism in 
long-term grafts, which may have an influence on graft stability, we analyzed the 
presence of recipient-derived hepatocytes in liver biopsies by a multiplex STR typing kit. 
We compared the proportions of recipient-derived hepatocytes between long-term stable 
grafts and dysfunctional grafts (i.e., having chronic rejection) of similar follow-up 
periods to examine whether microchimerism exerts any influence on the long-term fate 
of grafts. Fluorescence in situ hybridization (FISH) for X and Y chromosomes was also 




The aim of this study was to use STR-based genotyping to analyze donor hepatocyte 
replacement by recipient cells in liver allografts in relation to the long-term outcome 
(stable graft or chronic rejection) after liver transplantation. For quantitative 
evaluation of the degree of microchimerism, FISH for X and Y chromosomes was used 
additionally in cases of female-to-male transplantation. 
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3. Material and Methods 
Patients 
This retrospective study reviewed the files of the Department of Diagnostic Pathology of 
Kyoto University Hospital, and selected, from among 117 pediatric liver transplant 
patients, those who received liver allografts from living donors and who underwent 
their last biopsies at 10 years post-transplant from August 2006 to August 2008. All 
subjects were 18 years of age at the time of liver transplantation and had received liver 
grafts from their parents. 
The study subjects were divided into two groups. The first group consisted of 13 patients 
who survived with the initial grafts, who had available records on their 10-year protocol 
biopsies, and whose liver function tests were normal (stable graft (SG) group). The 
patients in this group showed no histological signs of rejection in the absence of 
immunosuppression or a low maintenance dose of tacrolimus at the time of their last 
biopsy. The second group consisted of 11 patients who survived with the initial grafts, 
but who experienced graft dysfunction after a follow-up period similar to the stable 
group (late dysfunctional graft (LDG) group). The diagnoses of graft dysfunction were 
chronic rejection (CR, n = 3) and idiopathic post-transplantation hepatitis (IPTH, n = 8). 
The demographic data of the recipients and donors are shown in Table 1. 
This study was approved by the Kyoto University Review Board (No. G504). 
 
Definition of late graft dysfunction and histological assessments 
Histological analysis was performed on formalin-fixed paraffin-embedded tissue 
samples. Morphological findings were assessed using hematoxylin and eosin staining 
(H&E), Masson’s trichrome staining, and immunohistochemical staining for cytokeratin 
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7 of the bile duct epithelium. Liver biopsy specimens were assessed by pathologists 
(AM-H, and HH). Chronic rejection (CR) can be defined as immune-mediated damage to 
the liver allograft, which is characterized histologically by two main features: loss of 
small bile ducts and an obliterative vasculopathy that affects large- and medium-sized 
arteries [22]. Idiopathic post-transplantation hepatitis (IPTH) can be defined as chronic 
hepatitis after liver transplantation for which the causes are unknown. IPTH responds 
to steroids, but if untreated, the condition could progress to cirrhosis and graft failure 
[23]. IPTH and late acute rejection are likely to be parts of an overlapping spectrum of 
immune-mediated damage [24]. 
 
Postoperative clinical data were collected retrospectively. Laboratory data at the time of 
protocol biopsies for stable patients and at the time of diagnosis of post-transplant CR 
and IPTH included the following variables: serum aspartate aminotransferase (AST, 
normal range, 13-29 IU/l), alanine aminotransferase (ALT, 8-28 IU/l) and total bilirubin 
(T-Bil, 0.2-1.0 mg/dl).  
 
Laser capture microdissection and DNA extraction 
To identify donor and recipient alleles, DNA from the explanted recipient native livers 
and normal liver samples obtained from each donor liver at transplantation was 
analyzed without microdissection. For the post-transplant liver allograft biopsy 
specimens, laser capture microdissection of hepatocyte nuclei was performed using the 
PALM Laser-MicroBeam system (P.A.L.M, Wolfratshausen, Germany). Only the nuclei 
of hepatocytes were microdissected in order to avoid blood cells. Paraffin sections (4 μm 
thick) were deparaffinized and lightly stained with toluidine blue. At least 1000 
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hepatocyte nuclei were dissected from stable grafts (n = 13) and 11 samples of late graft 
dysfunction (Figure 1). The laser spot size was set in 6 μm, the size of hepatocyte nuclei 
[25]. After collecting the cells onto the lid of a tube, the DNA was isolated using the 
QIAamp DNA FFPE Tissue Kit (QIAGEN, Venlo, the Netherlands). 
 
Short tandem repeat (STR) PCR 
Three liver tissue samples for each case, including the recipient’s explanted native liver, 
the donor liver (pre-implantation liver tissue) and the long-term-followed allograft were 
used for detecting graft chimerism. We used the AmpFlSTR® Identifiler® PCR 
Amplification Kit (Life Technologies, Carlsbad, CA, USA) to perform STR-PCR. The 15 
STR loci amplified in this reaction included: D8S1179, D21S11, D7S820, CSF1PO, 
D3S1358, TH01, D13S317, D16S539, D2S1338, D19S433, vWA, TPOX, D18S51, 
D5S818, and FGA. PCR was performed using 1 ng of genomic DNA in a final reaction 
volume of 25 μl. The PCR cycle conditions were: 95°C for 11 min, followed by 31 cycles at 
94°C for 1 min, 59°C for 1 min and 72°C for 1 min. The final elongation step was 45 min 
at 60°C. The PCR products were analyzed with an ABI PRISM® 310 Genetic Analyzer 
(Life Technologies, Carlsbad, CA, USA). 
 
 
In situ hybridization for X and Y chromosomes 
After proteinase K treatment, FISH was performed on pretreated slides for the X 
chromosome (chromosome enumeration probe [CEP] X, spectrum green) and Y 
chromosome (CEP Y, spectrum red) (Abbott Molecular, Inc., Des Plaines, IL, USA). The 
slides were denatured for 10 min at 73°C and hybridized overnight at 37°C in an 
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incubation chamber. DAPI (4’,6-diamidino-2-phenylindole) was used for nuclear 
counterstaining (Vysis, Inc., Downers Grove, IL, USA). The slides were analyzed under 
fluorescence microscopy at a magnification of 600. We focused on hepatocytes, which 
were recognized via their morphology and location within the plates. Grafts from 
female-to-female transplantation or male-to-male transplantation were stained as 
controls. The percentage of hepatocyte chimerism was calculated by counting 100 
hepatocytes for each slide for sex-mismatched cases; in particular, chimeric hepatocytes 
can be identified by the presence of a Y chromosome signal in female-to-male liver 
transplantation. Because a proportion of polyploid hepatocytes is normally present in 
the liver [26], an XX signal in male grafts transplanted to female patients could not be 
counted as recipient-derived cells as it might be a sectioning artifact [25]. 
  
Statistical analysis 
Quantitative data were expressed as mean ± SD. Student’s t-test was used to compare 
continuous variables. The chi-square test or Fisher’s exact test was used to compare 
frequencies of categorical variables. Statistical analysis was performed using StataSE 








Laboratory and histological findings 
The first group, the SG group, was composed of 13 patients who exhibited normal liver 
function test results after a long-term follow-up period (10.8 ± 2.2 years). The causes for 
liver transplantation in this group were biliary atresia in 12 patients and congenital 
biliary dilatation in one patient. Ten of the patients received left or lateral grafts from 
their mother, and 3 received grafts from their father. Patients with SGs received either 
a low maintenance dose of tacrolimus monotherapy (trough level <1.5 ng/ml), or had the 
tacrolimus discontinued at the time of the last protocol biopsy. There were minimal 
histological abnormalities, including slight perivenular fibrosis and non-specific mild 
inflammatory changes (Figure 2A). No vascular or biliary complications were found in 
any of the SG patients. 
 
The second group, the LDG group, was composed of 8 patients with IPTH (Figure 2B) 
and 3 with CR (Figure 2C). The original diseases in this group were congenital biliary 
atresia in 10 patients and Wilson’s disease in one patient. The patients survived with 
their initial grafts, but exhibited abnormal liver function test results after a follow-up 
period similar to the SG group (11.2 ± 2.4 years). Six of the LDG patients received left or 
lateral grafts from their mother, and 5 received grafts from their father. 
There were significant differences in the liver function test results and age in recipients 
and donors between the SG and LDG groups at 10 years post-transplant (p < 0.05) 
(Table 1). All patients in the LDG group were treated with a triple immunosuppression 
regimen of tacrolimus, prednisolone, and mycophenolate mofetil. 
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STR-PCR after laser microdissection 
Although normal women with a previous male pregnancy can have a Y chromosome in 
their liver [29,30], none of the female donor livers revealed maternal chimerism in our 
study. 
 
A total of 72 samples from 24 recipients (13 recipients with stable grafts, and 11 
recipients with graft dysfunction), taken from each recipient’s native liver, donor liver 
and allograft at 10 years post-transplant, were evaluated with Identifiler® STR kits 
(Life Technologies). Allele peaks detected allografts at 10 years, and were compared 
with the recipient and donor samples to determine if the amplified alleles originated 
from the recipient or donor or represented a mixture of both. There was a loss of signal 
on the longer-sized STR products, probably due to highly degraded and fragmented 
DNA molecules on formalin-fixed paraffin-embedded sections. Since all donors were the 
parents of the recipients, at least one of the alleles was shared between donor and 
recipient. When the recipient and donor had two distinct alleles for a given marker 
(heterozygosity), the appearance of one allele from the recipient not shared between the 
donor and recipient at any STR loci indicated hepatocyte chimerism in the allograft 
(Figure 3A). When two of the STR alleles were shared between donor and recipient, the 
marker was not informative for chimerism; therefore, the STR loci were not counted as 
informative signals. As a result, the mean number of informative STR loci showing 
signals was 2.0 ± 1.3 in 24 allografts. Hepatocyte chimerism was found in 7 of 13 cases 
(54%) in the SG group and 5 of 11 cases (45%) in the LDG group (p = 0.68). The STR loci 
that exhibited recipients’ alleles in the allografts are shown in Table 2. The STR loci 
that provided shorter amplified PCR products less than 250 bp long, such as D3S1358, 
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D5S818, D8S1179, D19S433 and vWA, allowed a clear discrimination between recipient 
and donor. One case showed a recipient allele for the longer fragment locus CSF1PO 
(281-317 bp long). 
 
XY chromosomes in situ hybridization 
After laser microdissection and STR-PCR analysis, 3 of 24 recipient liver biopsy 
samples were obtained from male recipients receiving grafts from female donors; two in 
the SG group and one in the LDG group. The quantitative evaluation revealed one 
patient in the SG group and one in the LDG group who showed that 3.4% (6/175 
hepatocytes) of hepatocytes and 2.5% (3/120) of hepatocytes were XY-configured 
hepatocytes, respectively (Figure 3B). Thus, the proportion of hepatocyte chimerism 
was low in both groups [25]. One case in the SG group revealed no evidence of 






We confirmed that hepatocyte chimerism was present at high frequencies in human 
liver allografts in our study subjects. In a previous report by Kleeberger [11], hepatocyte 
chimerism was reported to be present in a high percentage as analyzed by laser 
microdissection followed by microsatellite analysis; i.e., 41% in the 27 
post-transplantation liver biopsies. A study by Ng et al. [4] found 80% in the 10 
post-transplantation liver biopsies. 
The biological significance of chimeric cells is controversial. Hepatocyte chimerism 
seems to be triggered by extensive liver cell turnover as it occurs in chronic active 
hepatitis reported by Kleeberger [11]. However, in our study, we found that the degree of 
hepatocyte chimerism observed long after liver transplantation was not different in SG 
and LDG patients and did not seem to depend on the degree of hepatic injury. Ng et al. 
[4] found that only up to 1% of recipient-derived cells show hepatocyte differentiation, 
and that most liver allografts have only mild nonspecific changes. In addition, the 
severity of acute cellular rejection appears to have no effect on the rate of 
recipient-derived repopulation [12]. 
 
Obtaining DNA for molecular analysis from formalin-fixed, paraffin-embedded (FFPE) 
tissue is a challenge. When fixing is performed too long, it can cause damage to nucleic 
acids by extensive cross-links between proteins in the tissues and DNA fragmentation. 
DNA from FFPE tissue is often scarce, degraded, and can contain substances that 
inhibit the molecular procedures, leading to low quality DNA. FFPE tissues stored for 
long periods have shown a lower rate of amplification in the PCR reaction than that of 
recent FFPE samples [27]. The standard protocol of the AmpFlSTR® Identifiler® PCR 
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Amplification Kit can produce results with DNA templates of more than 100 pg, 
approximately 16 diploid cells [28]. For FFPE tissue samples, even if a large number of 
cells is contained, highly degraded DNA may result in poor PCR amplification [27]. Our 
FFPE samples were not uniform with respect to time of fixation and storage time of the 
blocks in each case, which could explain the low PCR amplification rate and the 
variation of PCR amplification products and frequent loss of signals in our study. 
Quantitation of STR PCRs may not be feasible for highly degraded FFPE samples; thus, 
positivity for multiple recipient-specific loci (compared to one) in the graft may not 
represent a higher extent of chimerism. Even if 1,000 dissected nuclei are contaminated 
by a few blood cells, this minor contamination in the DNA fragment will not be 
amplified [28]. 
 
One case in the present study displayed hepatocyte chimerism on FISH, but no evidence 
of chimerism in STR-PCR. Generally, FISH methodologies underestimate the extent of 
chimerism because of sectioning and/or suboptimal hybridization efficiency [6,7,10]. 
Because of highly degraded DNA from FFPE tissue, the case in the present study had 
only one STR locus that was informative for chimerism. Including the result of FISH, 8 
recipients in the SG group and 5 recipients in the LDG group showed hepatocyte 
chimerism; these findings were not statistically significant (p = 0.43). 
 
It is yet unknown whether recipient-derived hepatocytes originate either by adult 
progenitor-cell transdifferentiation or by fusion between stem cells and donor 
hepatocytes [31]. Adult bone marrow-derived stem cells have been capable of 
differentiating into hepatic cells in the rat [17] and the human [10,32], but the level of 
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hepatocyte replacement after bone marrow transplantation has been reported to be 
quite low [33]. Five percent of recipient-derived hepatocytes become detectable only 
after granulocyte colony-stimulating factor (G-CSF) treatment post-liver 
transplantation, suggesting that stem cell mobilization initiates microchimerism in 
hepatocytes [31]. G-CSF treatment or bone marrow cell infusion in patients with 
chronic liver disease leads to improvement of liver function, which suggests the 
contribution of engrafted chimeric cells in liver regeneration [34-36]. However, in our 
study, we found that the extent of engraftment of recipient-derived hepatocytes was 
very small in both the SG and LDG groups, comprising 3% of counted hepatocytes. The 
degree of liver cell chimerism did not seem to influence graft outcome. Eleven of the 16 
samples obtained from recipients with sex-mismatched grafts demonstrated 
recipient-derived hepatocyte repopulation, comprising a mean of 2.1% of the 
hepatocytes, similar to our result [12]. We concluded that the chimerism was a constant 
event, and that liver injury was not necessary to achieve hepatocyte replacement by 
bone marrow-derived cells [33]. This result was in agreement with the report in renal 
transplantation in which tubular epithelium replacement by recipient cells is observed 




In the present study, STR-based genotyping after laser microdissection revealed a high 
percentage of chimeric hepatocytes in allografts long after liver transplantation. No 
correlation was found with allograft outcome. Evaluation of the Y chromosomes by in 




Laser microdissection of hepatocyte nuclei. Sequence of pictures showing dissection of a 
hepatocyte by laser microdissection. The laser spot size is set in 6 μm, the size of 
hepatocyte nuclei (middle figure). The hepatocyte nuclei are dissected selectively and 
catapulted into the lid of the tube (lower figure).  
 
Figure 2. Histological findings of stable graft (A) and late dysfunctional graft (B and C). 
(A) Stable graft showing no remarkable change (HE, original magnification, 200). 
(B) Idiopathic post-transplant chronic hepatitis showing bridging fibrosis with mild 
interface change (HE, original magnification, 200). 
(C) Atrophy of portal tract and loss of bile ducts in chronic rejection. No recognizable 
interlobular bile duct on CK7 immunostaining (original magnification, 200). A, hepatic 
artery; P, portal vein. 
 
Figure 3. Hepatocyte microchimerism in long-term allograft. 
(A) Chimeric allotype in long-term hepatocyte allograft post-transplant by short-tandem 
repeat PCR. 
(B) Fluorescence in situ hybridization for X (green) and Y (red) chromosomes. Y 
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(n = 13) 
Patients with late 
dysfunctional 
grafts (n = 11) 
p values 
Age at LT (mean ± SD) (yr) 1.2 ± 1.3 6.7 ± 5.3 0.002* 
Recipient gender (female) 10 (77%) 9 (82%) 0.77 
Time since LT (yr) 10.8 ± 2.3 11.2 ± 2.5 0.69 
Donor age (yr) 31 ± 3.9 36 ± 5.7 0.01* 
Donor gender (female) 10 (77%) 6 (55%) 0.25 
AST (IU/l) 28 ± 4.8 126 ± 76 <0.001* 
ALT (IU/l) 23 ± 7.4 156 ± 197 0.02* 
T-Bil (mg/dl)  0.9 ± 0.3 4.7 ± 6.9 0.06 
 
 
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BA, 





Table 2: The result of hepatocyte chimerism analyzed by microsatellite analysis and 
























     
1 SG 0 F-F  – 1 (D19) 
2 SG 0 F-F  D3 3(D3, D5, D8) 




– 1 (D3) 
4 SG 0 F-F  D19 1 (D19) 
5 SG 1 F-F  D7, D18, CSF 3(D7, D18,CSF) 
6 SG 1 F-F  – 3(D3,D7,D19) 
7 SG 1 M-F  D3 1 (D3) 
8 SG 1 F-F  – 1 (TH) 
9 SG 1 F-F  D8 1 (D8) 








11 SG 3 F-F  D3, D8, D19, vWA 
4 (D3,D8,D19, 
vWA) 
12 SG 3 M-F  – 3 (D3,D8,TH) 
13 SG 4 M-M  D3, D5 3 (D3, D5, vWA) 
Late dysfunctional graft 
group 
    
14 IPTH 1 F-F  – 1 (TH) 





4 (D3, D5, D8, 
D19) 
16 CR 2 F-F  D19 2 (D3, D19) 
17 IPTH 4 M-F  – 1 (D3) 
18 CR 5 F-F  – 1 (D3) 
19 IPTH 6 F-F  D19 1 (D19) 
20 IPTH 6 M-M  – 1 (D3) 
21 IPTH 7 M-F  D16 1 (D16) 
22 IPTH 8 M-F  – 2 (D3, D5) 
23 CR 15 M-F  D3, D8 2 (D3, D8) 
24 IPTH 18 F-F  – 1 (D13) 
 
Abbreviations: CR, chronic rejection; D-R, donor-recipient; F, female; FISH, fluorescence 
in situ hybridization; IPTH, idiopathic post-transplantation hepatitis; M, male; SG, 
stable graft; STR, short tandem repeat 
D3, D3S1358; D5, D5S818; D7, D7S820; D8, D8S1179; D13, D13S317; D16, D16S539; 
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